REG - Alliance Pharma PLC - CULS Conversion and Additional Listing <ALAPH.L>
.
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100510:nRSJ6514La
RNS Number : 6514L
Alliance Pharma PLC
10 May 2010
For immediate release 10 May 2010
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
CULS Conversion and Additional Listing
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 10 May 2010 it received a
conversion notice in respect of £200,000 nominal value of the Company's 8% Convertible Unsecured Loan Stock.
Accordingly,
the Company has allotted 952,380 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to
admission
of the Ordinary Shares to trading on AIM.
Application has been made by Alliance for the 952,380 Ordinary Shares to be admitted to trading on AIM, and it is
expected
that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be
admitted to trading on 14 May 2010.
Following conversion and allotment, Alliance will have 228,961,056 Ordinary Shares and £6,225,000 of 8% Convertible
Unsecured Loan Stock in issue.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney
Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge
Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the
treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's
disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies
with
their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
